Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Seres Therapeutics (NASDAQ:MCRB), Inc., a pharmaceutical company, announced the implementation of a 1-for-20 reverse stock split of its common stock, effective as of Monday. The adjustment occurred at 5:00 p.m. Eastern Time on April 21, 2025, and trading on The Nasdaq Global Select Market commenced on a split-adjusted basis under the existing ticker symbol "MCRB" today. According to InvestingPro data, the stock has experienced significant pressure, with a 52-week trading range of $7.20 to $30.60, and a notable decline of 55% year-to-date.
This corporate action follows the approval by Seres’ stockholders at the Annual Meeting on April 10, 2025, to authorize the Board of Directors to execute a reverse stock split at a ratio determined by the Board within a range of 1-for-5 to 1-for-50. The Board finalized the 1-for-20 ratio and discarded other potential ratios on the same date. The company faces financial challenges, with InvestingPro data showing a debt-to-equity ratio of 6.65 and negative EBITDA of $115.85 million in the last twelve months.
The reverse stock split consolidated every 20 shares of issued and outstanding common stock into one share. The company’s authorized shares and the par value per share remain unchanged. Shareholders owning fractional shares as a result of the consolidation will receive a cash payment instead of fractional shares.
The new CUSIP number assigned to Seres Therapeutics’ common stock after the reverse stock split is 81750R 201. The company’s filing, including the full text of the Charter Amendment, is detailed in the Current Report on Form 8-K, which is incorporated by reference.
The company cautions that this report contains forward-looking statements which are subject to risks and uncertainties that could cause actual results to differ from those anticipated. These statements include potential impacts of the reverse stock split and adjustments for fractional shares. With the next earnings report due on May 7, 2025, investors seeking deeper insights can access comprehensive analysis and 14 additional key metrics through InvestingPro’s detailed research reports, which provide essential data for informed investment decisions.
The information presented in this article is based on the statements made in the aforementioned SEC filing by Seres Therapeutics, Inc.
In other recent news, Seres Therapeutics reported a significant miss in its fourth-quarter 2024 earnings, with an earnings per share (EPS) of -$0.81 against a forecast of -$0.20. The company posted a net loss of $15.7 million for the quarter, an improvement from a $34.7 million loss in the same period the previous year. Despite these financial challenges, Seres Therapeutics is advancing its lead program, SER-155, with promising clinical results. Additionally, the company has implemented operational cost reductions, notably in research and development and general and administrative expenses. In governance news, Seres Therapeutics approved a new stock incentive plan and a reverse stock split at a ratio of 1-for-20, which will take effect shortly. Shareholders endorsed the 2025 Incentive Award Plan, replacing the 2015 plan, and elected three Class I directors. PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2025. These developments reflect Seres Therapeutics’ ongoing efforts to streamline operations and focus on its core therapeutic areas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.